Agastiya Biotech

Executive Summary

Agastiya Biotech is a private, next-generation oncology company based in Cambridge, MA, founded in 2021. The company leverages systems biology, immunotherapy, and quantum biophysics to develop breakthrough cancer treatments. Its lead molecule, AB001, is a first-in-class, tumor-agnostic, orally available therapeutic designed to transform cancer care across multiple indications. With a novel mechanism of action and oral administration, AB001 has the potential to address significant unmet needs in oncology, though the company remains in early development stages with no disclosed funding or clinical data. The scientific approach is innovative but unproven, and the lack of publicly available milestones or financial backing introduces uncertainty. Nonetheless, the tumor-agnostic and oral profile provides a differentiated value proposition if clinical validation is achieved.

Upcoming Catalysts (preview)

• Q2 2027Initiation of Phase 1 Clinical Trial for AB00125% success
• Q1 2027IND Filing or Regulatory Clearance40% success
• TBDPartnership or Licensing Deal20% success